Home Tags Brentuximab

Tag: Brentuximab

ISHL 2016: Seattle Genetics Commits to Improving Hodgkin Lymphoma Treatment

In a pre-conference announcement before the start of 10th International Symposium on Hodgkin Lymphoma (ISHL) taking place at the Gürzenich in Cologne, Germany, October 22-25,...

Trial Shows 92% Objective Response Rate in the Evaluation of Brentuximab...

Data presented at the 2014 Annual Bone Marrow Transplant (BMT) Tandem Meetings organized by The American Society for Blood and Marrow Transplantation and the Center for International Blood & Marrow Transplant Research being held in Grapevine (Dallas), Texas, February 26 - March 2, 2014, highlights the benefits of brentuximab vedotin (Adcetris®; Seattle Genetics) in various treatment schedules for hard to treat cancers.

Brentuximab Vedotin Shows 42% Objective Response Rate in Patients with Relapsed...

New, updated, data from a phase II clinical trial of brentuximab vedotin (Adcetris®; Seattle Genetics) in patients with diffuse large B-cell lymphoma or DLBCL and other B-cell non-Hodgkin lymphomas, demonstrated an encouraging activity and tolerability profile in the relapsed and refractory setting. The results were presented at the 55th annual meeting of ASH®, the American Society of Hematology, held in New Orleans, Louisiana, USA, from December 7 - 10, 2013.

Phase III Front-line Trial Planned with Brentuximab Vedotin in Advanced Stage...

Interim results from a phase I clinical trial of brentuximab vedotin(SGN-35, Adcetris™, Seattle Genetics/Millennium: The Takeda Oncology Company) in combination with chemotherapy for the...

Updated Data for Brentuximab Vedotin Shows Durable Complete Remission and Manageable...

Updated data from a pivotal trial of single-agent brentuximab vedotin (adcetris™,Seattle Genetics) in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)...

Data on Brentuximab Vedotin Highlights Positive Findings and Clinically Meaningful Durations...

Data reported today demonstrating that prolonged treatment with Brentuximab Vedotin (SGN-35; Adcetris™, Seattle Genetics) beyond 16 cycles of therapy was associated with clinically meaningful...

Majority of Pediatric Patients with Hodgkin Lymphoma Achieve CR After Treatment...

Six out of nine pediatric patients with relapsed or refractory Hodgkin lymphoma (HL) (n=5)or systemic anaplastic large cell lymphoma (sALCL) (n=4)achieved complete remission (CR)...

Brentuximab Offers Promising New Treatment Option for Patients with Relapsed or...

While 70 to 80% of all newly diagnosed patients with adult Hodgkin lymphoma are typically cured with combination chemotherapy of three or four agents...

Phase I Trial of Loaded Antibody Establishes Dose, Catalogues Side Effects...

An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38% of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in...

Pivotal Trial In Relapsed And Refractory Hodgkin Lymphoma Shows Positive Results...

Results of a pivotal clinical trial with of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30 shows that the trial drug...

FEATURED RESOURCES